Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
出版年份 2015 全文链接
标题
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
作者
关键词
Immunotherapy, Metastatic castration-resistant prostate cancer, Prostate cancer, Sipuleucel-T
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 64, Issue 6, Pages 655-663
出版商
Springer Nature
发表日期
2015-05-29
DOI
10.1007/s00262-015-1707-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
- (2014) E J Small et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
- (2014) D. G. McNeel et al. Cancer Immunology Research
- Prostate cancer: ESMO Consensus Conference Guidelines 2012
- (2013) A. Horwich et al. ANNALS OF ONCOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- The expanding role(s) of eosinophils in health and disease
- (2012) E. A. Jacobsen et al. BLOOD
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) J. L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) P. W. Kantoff et al. JNCI-Journal of the National Cancer Institute
- Re: Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) C. G. Drake JNCI-Journal of the National Cancer Institute
- Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
- (2012) M. L. Huber et al. JNCI-Journal of the National Cancer Institute
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research
- (2011) J. L. Gulley et al. CLINICAL CANCER RESEARCH
- Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
- (2011) Simon J. Hall et al. JOURNAL OF UROLOGY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- CD54 is a surrogate marker of antigen presenting cell activation
- (2008) N. A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started